¼¼°èÀÇ ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Unit Drug Dose Delivery Systems
»óǰÄÚµå : 1737455
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,082,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,248,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 475¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 375¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 475¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÃ¶ó½ºÆ½ ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛÀº CAGR 3.7%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 245¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯¸® ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 102¾ï ´Þ·¯, Áß±¹Àº CAGR 7.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 102¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 96¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¾î ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.6%¿Í 3.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ¿øµ¿·Â Á¤¸®

´ÜÀ§ ¿ë·® Àü´Þ ½Ã½ºÅÛÀÌ Åõ¾à °ü¸®ÀÇ Ç¥ÁØÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¾à¹° Àü´Þ ½Ã½ºÅÛÀº ƯÈ÷ º´¿ø, Àå±â ¿ä¾ç, ±×¸®°í ÃÖ±Ù¿¡´Â ÀçÅÃÄ¡·á ȯ°æ¿¡¼­ Çö´ë ÀǾàǰ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ºí¸®½º ÅÍ ÆÑ, µð½ºÆæ½Ì, ¾ÚÇÃ, ÇÁ¸®Çʵå½Ã¸°Áö µî 1ȸ¿ë ÀÏȸ¿ë Æ÷Àå ¹× Á¶Á¦ ½Ã½ºÅÛÀ» ÅëÇØ Á¤È®ÇÑ Åõ¾àÀ» º¸ÀåÇϰí, Åõ¾à ¿À·ù¸¦ ÁÙÀ̸ç, Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­Çϰí Àç°í °ü¸®¸¦ °³¼±ÇÏ¸ç º´¿ø ³» °¨¿°À» ÁÙÀ̱â À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó ´ÜÀ§ ¿ë·® Çü½ÄÀº °æ±¸¿ë ÀǾàǰ°ú ºñ°æ±¸¿ë ÀǾàǰ ¸ðµÎ¿¡ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. º´¿ø¿¡¼­´Â ÀÚµ¿ Æ÷Àå±â ¹× ´ÜÀ§ ¿ë·® īƮ¸¦ Ȱ¿ëÇÏ¿© Åõ¾à ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ´Â ÇÑÆí, ȯÀÚµéÀº ¸íÈ®ÇÑ ¶óº§¸µ°ú »ç¿ë ÆíÀǼºÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ƯÈ÷ °í·ÉÀÚ ¹× ´Ù¾àÁ¦ º¹¿ë ȯÀÚ Áõ°¡·Î ÀÎÇØ ¾à¹° Ä¡·á°¡ º¹ÀâÇØÁü¿¡ µû¶ó ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ±â°ü°ú ÀÇ·á ÀÎÁõ ±â°üÀº ȯÀÚ ¾ÈÀü ¸ñÇ¥¿¡ ºÎÇÕÇϵµ·Ï ´ÜÀ§ ¿ë·® °üÇàÀÇ Ã¤ÅÃÀ» Àå·ÁÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Àü ¼¼°è Ç¥ÁØ ÀǾàǰ ¾÷¹«¿¡ ´õ¿í ÅëÇյǰí ÀÖ½À´Ï´Ù.

ÀÚµ¿È­¿Í Æ÷Àå ±â¼úÀº ´ÜÀ§ ¿ë·® Àü´ÞÀ» ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Æ÷Àå ÀÚµ¿È­, Àç·á °úÇÐ ¹× Á¦ÇüÈ­ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ À¯¿ë¼º°ú È®À强ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °í¼ÓÀÇ Á¤¹ÐÇÑ ºí¸®½º ÅÍ Æ÷Àå ¶óÀÎ, RFID Áö¿ø ÃßÀû ½Ã½ºÅÛ, ·Îº¿À» ÀÌ¿ëÇÑ ´ÜÀ§ ¿ë·® Æ÷ÀåÀ¸·Î ȯÀÚº° Åõ¾à ¿ä¹ýÀ» ´ë·®À¸·Î ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ¿Í ÇÔ²², µà¾ó è¹ö ÁÖ»ç±â, ÀÚµ¿ ºñȰ¼ºÈ­ ÁÖ»ç±â, ÀÏȸ¿ë ÈíÀԱ⠵îÀÇ ±â¼ú Çõ½ÅÀº »çÀü ÃæÀüµÈ ÀÏȸ¿ë Åõ¿© ÇüÅÂÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. 1ȸ¿ë Æ÷Àå ¿ª½Ã º¯Á¶ ¹æÁö, ¼Ò¾Æ ³»¼º, ȯ°æ ģȭÀû ¼³°è°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, Áö¼Ó°¡´É¼º Àǹ«È­¿¡ µû¶ó ÀçȰ¿ë ¹× »ýºÐÇØ¼º ¼ÒÀç°¡ Àα⸦ ²ø°í ÀÖÀ¸¸ç, 3D ÇÁ¸°ÆÃ°ú ½º¸¶Æ® Æ÷ÀåÀÇ ºÎ»óÀ¸·Î ȯÀÚÀÇ ¾à¸®À¯ÀüÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó ´ÜÀ§ ¿ë·®¿¡ ¸Â°Ô Á¶Á¤ÇÏ´Â °³ÀÎ ¸ÂÃãÇü ¾à¹° Àü´ÞÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ȯÀÚÀÇ ¾à¸®À¯ÀüÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó ¿ë·®À» Á¶ÀýÇÏ´Â °³ÀÎ ¸ÂÃãÇü ¾à¹° Àü´ÞÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ Ä¿³ØÆ¼µå Àü´Þ ½Ã½ºÅÛ ¹× µðÁöÅÐ Á¤Á¦ µð½ºÆæ¼­´Â ÀÓ»ó½ÃÇè ¹× ¸¸¼º Áúȯ °ü¸®¿¡¼­ ½Ç½Ã°£ ¼øÀÀµµ ¸ð´ÏÅ͸µÀ» À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼¿¡ µû¶ó ´ÜÀ§ ¿ë·®Àº ±âº»ÀûÀÎ ¾ÈÀü ´ëÃ¥¿¡¼­ µðÁöÅÐ ±â¹ÝÀÇ È¯ÀÚ Á᫐ Àü´Þ »ýŰè·Î º¯È­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ÀçÆíÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â ±ÔÁ¦, ¿î¿ë, ¼ÒºñÀÚ µ¿ÇâÀº?

¾àǰÀÇ ¾ÈÀü¼º, ¾àǰ À¯Ãâ, º¹¾à ¼øÀÀµµ¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö¸é¼­ FDA, EMA, WHO µî ±ÔÁ¦ ±â°üÀº ƯÈ÷ ±ÔÁ¦ ¾à¹°, ¼Ò¾Æ¿ë ÀǾàǰ, °íÀ§Çè ¾à¹°¿¡ ´ëÇØ ´ÜÀ§ Åõ¾àÀ» ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. º´¿ø°ú ¾à±¹Àº Joint Commission(°øµ¿À§¿øÈ¸) ¹× USP <:800>&ÀÇ ±âÁØÀ» ÁؼöÇÏ´Â ¾à¹° °ü¸® ½Ã½ºÅÛÀ» µµÀÔÇØ¾ß ÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â Áß¾Ó ÁýÁᫎ Æ÷Àå ½Ã½ºÅÛ°ú ¹ÙÄÚµå ½ºÄ³´×À» ÅëÇØ °ü¸® ½Ã°£À» ´ÜÃàÇϰí Àç°í¸¦ Á¤È®ÇÏ°Ô ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼ÒºñÀÚ Â÷¿ø¿¡¼­´Â Àα¸ °í·ÉÈ­, ¸¸¼ºÁúȯÀÇ À¯Çà, ÀçÅÃÀÇ·á·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ »ç¿ëÇϱ⠽±°í ¹Ù·Î º¹¿ëÇÒ ¼ö ÀÖ´Â ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¿ÇÁÄÉ¾î Æ®·»µå¿Í OTCÀÇ ¼ºÀåÀº ¿µ¾çº¸ÃæÁ¦, ÇǺΰú, ¿©¼º °Ç°­ µî ½ÃÀå¿¡¼­ 1ȸ¿ë ¾àǰÀÇ º¸±ÞÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ Áöħ, ¿öÅ©Ç÷οìÀÇ ÃÖÀûÈ­, ¼ÒºñÀÚ ±â´ëÄ¡ÀÇ ÁøÈ­¿Í ÇÔ²² Ä¡·á ¹× Äɾî Àå¸é¿¡¼­ ´ÜÀ§ ¿ë·® ¸ðµ¨ÀÇ ÁøÈ­°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¼¼°è ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¾à¹° ¿À·ù ¹ß»ý·ü Áõ°¡, °¨¿° °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÓ»ó ¹× ÀçÅà ġ·á ȯ°æ¿¡¼­ Á¤¹ÐÇÑ ¾à¹° °ü¸®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿ Á¶Á¦ ¹× ½º¸¶Æ® ÆÐŰ¡ ±â¼úÀÇ ¹ßÀüÀº º´¿ø¿¡¼­ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ´ç´¢º´, õ½Ä, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀ» °ü¸®ÇÏ´Â ¼ÒºñÀÚµé »çÀÌ¿¡¼­´Â ¹Ì¸® °è·®µÈ Åõ¾à ÇüŰ¡ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀçÅÃÀÇ·á¿Í ¿ø°ÝÀÇ·áÀÇ È®´ë´Â Àü¹®°¡ÀÇ °¨µ¶ ¾øÀ̵µ ¾à¹° º¹¿ëÀ» ÁؼöÇÒ ¼ö ÀÖ´Â Á÷°üÀûÀ̰í ÈÞ´ë °¡´ÉÇÏ¸ç ¾ÈÀüÇÑ ´ÜÀ§ ¿ë·® Åõ¾à ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ȯÀÚ Àü¿ë º¹¿ë·® ÆÑ, ½ÃÇè¿ë ŰƮ, µðÁöÅÐ ¼øÀÀµµ Ç÷§ÆûÀ¸·Î Áö¿øµÇ´Â °³ÀÎ ¸ÂÃãÇü ¿ä¹ýÀ» °³¹ßÇÏ¿© ÀÌ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× °ø±Þ¸Á ¿öÅ©Ç÷ο쿡 ´ÜÀ§ Åõ¾à ½Ã½ºÅÛÀ» ÅëÇÕÇÏ¿© ¾àǰÀÇ ÃßÀû¼ºÀ» ÃÖÀûÈ­ÇÏ°í ³¶ºñ¸¦ ÁÙÀ̰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, ±â¼ú Çõ½Å, ÃÖÁ¾ »ç¿ëÀÚÀÇ ¼±È£µµ°¡ ÀÏÄ¡ÇÔ¿¡ µû¶ó ´ÜÀ§ ¿ë·® Åõ¿© ½Ã½ºÅÛÀº ÃֽŠÀǾàǰ ¹°·ù ¹× ȯÀÚ Áß½É Ä¡·á ¸ðµ¨ÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Àç·á(ÇÃ¶ó½ºÆ½ ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ, À¯¸® ´ÜÀ§ ¾à¹° ¿ë·® Àü´Þ ½Ã½ºÅÛ, ±âŸ Àç·á), Æ÷Àå À¯Çü(ºí¸®½ºÅÍ Æ÷Àå, ÇÁ¸®ÇÊ·¯ºí ½Ã¸°Áö£¦Ä«Æ®¸®Áö, ¹ÙÀ̾ˣ¦¾ÚÇÃ, ±âŸ Æ÷Àå À¯Çü), Á¦Ç° ÇüÅÂ(°íü Á¦Ç° ÇüÅÂ, ¾×ü Á¦Ç° ÇüÅÂ, ºÐ¸» Á¦Ç° ÇüÅÂ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 41°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ÀÇ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Unit Drug Dose Delivery Systems Market to Reach US$47.5 Billion by 2030

The global market for Unit Drug Dose Delivery Systems estimated at US$37.5 Billion in the year 2024, is expected to reach US$47.5 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Plastic Unit Drug Dose Delivery Systems, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$24.5 Billion by the end of the analysis period. Growth in the Glass Unit Drug Dose Delivery Systems segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.2 Billion While China is Forecast to Grow at 7.3% CAGR

The Unit Drug Dose Delivery Systems market in the U.S. is estimated at US$10.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.6 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Unit Drug Dose Delivery Systems Market - Key Trends & Drivers Summarized

Why Are Unit Dose Delivery Systems Becoming the Gold Standard in Medication Administration?

Unit drug dose delivery systems have become integral to modern pharmaceutical care, especially in hospital, long-term care, and increasingly in home healthcare environments. These systems involve the packaging and dispensing of drugs in pre-measured, single-use formats - such as blister packs, sachets, ampoules, or pre-filled syringes - to ensure accurate dosing, reduce medication errors, and improve treatment compliance. As global healthcare systems strive to minimize human error, improve inventory control, and reduce nosocomial infections, unit dose formats are being widely adopted for both oral and parenteral medications. Hospitals are leveraging automated dispensing machines and unit-dose carts to streamline administration workflows, while patients benefit from clear labeling and ease of use. With increasing complexity in drug regimens, particularly for elderly and polypharmacy patients, these systems play a critical role in enhancing therapeutic outcomes. Regulatory bodies and healthcare accreditation agencies are also encouraging the adoption of unit dose practices to align with patient safety goals, further embedding these systems into standard pharmaceutical operations worldwide.

How Are Automation and Packaging Technologies Transforming Unit Dose Delivery?

Technological advancements in packaging automation, materials science, and drug formulation are expanding the utility and scalability of unit drug dose delivery systems. High-speed, precision-oriented blister packing lines, RFID-enabled tracking systems, and robotic unit-dose packaging are enabling mass customization of patient-specific medication regimens. In parallel, innovations such as dual-chamber syringes, auto-disable injectors, and single-use inhalers are driving growth in pre-filled, disposable delivery formats. Unit dose packaging is also increasingly being designed to be tamper-evident, child-resistant, and environmentally friendly, with recyclable or biodegradable materials gaining traction in response to sustainability mandates. The rise of 3D printing and smart packaging is introducing personalized drug delivery, where unit doses are tailored to a patient’s pharmacogenetic profile. Mobile-connected delivery systems and digital pill dispensers are being deployed for real-time adherence monitoring in clinical trials and chronic disease management. These trends are transforming unit dosing from a basic safety measure into a digitally-enabled, patient-centric delivery ecosystem.

What Regulatory, Operational, and Consumer Trends Are Driving Market Realignment?

Growing concerns around medication safety, drug diversion, and adherence have prompted regulatory agencies such as the FDA, EMA, and WHO to advocate for unit dosing - especially in controlled substances, pediatric drugs, and high-alert medications. Hospitals and pharmacies are under pressure to adopt medication management systems that comply with Joint Commission and USP <800> standards, which favor unit dosing for accuracy and contamination control. Operational efficiency is also a major driver: healthcare providers are increasingly using centralized packaging systems and barcode scanning to reduce administration time and track inventory with precision. At the consumer level, aging populations, chronic disease prevalence, and the shift toward home-based care are fueling demand for easy-to-use, ready-to-administer medication formats. Self-care trends and OTC growth are further driving the uptake of single-use unit doses in markets such as nutraceuticals, dermatology, and women’s health. This confluence of regulatory directives, workflow optimization, and evolving consumer expectations is accelerating the evolution of the unit dose model across therapeutic and care settings.

What’s Driving the Growth of the Unit Drug Dose Delivery Systems Market Globally?

The growth in the unit drug dose delivery systems market is driven by several factors, including the rising incidence of medication errors, increasing emphasis on infection control, and growing demand for precision medication management in both clinical and homecare environments. Advances in automated dispensing and smart packaging technologies are fueling adoption in hospitals, while pre-measured dose formats are gaining popularity among consumers managing chronic illnesses such as diabetes, asthma, and cardiovascular disease. The expansion of home-based care and telemedicine is also promoting demand for intuitive, portable, and safe unit-dose devices that ensure compliance without the need for professional supervision. Pharmaceutical companies are responding by developing patient-specific dose packs, trial kits, and personalized regimens supported by digital adherence platforms. Additionally, healthcare providers are integrating unit-dose systems into electronic health records (EHRs) and supply chain workflows to optimize medication traceability and reduce waste. With regulatory support, technological innovation, and end-user preference aligning, unit dose delivery systems are positioned as a core pillar of modern pharmaceutical logistics and patient-centered care models.

SCOPE OF STUDY:

The report analyzes the Unit Drug Dose Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Material (Plastic Unit Drug Dose Delivery Systems, Glass Unit Drug Dose Delivery Systems, Other Materials); Packaging Type (Blister Packaging, Prefillable Syringes & Cartridges, Vials & Ampoules, Other Packaging Types); Product Form (Solid Product Form, Liquid Product Form, Powder Product Form)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â